Abstract
There is a growing body of evidence that COX-2 expression s a fundamental step in breast cancer pathogenesis acting through prostaglandin-dependent and independent mechanisms. Epidemiological studies suggest that NSAIDs confer a moderate degree of benefit against breast cancer. However further work is required to establish how this enzyme system can be best manipulated for therapeutic benefit.
Similar content being viewed by others
References
Sasco AJ (2003) Breast cancer and the environment. Horm Res 60(Suppl 3):50
Picot D, Loll PJ, Garavito RM (1994) The X-Ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367(6460):243–249
Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC (1999) Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 31(5):551–557
Smith WL, Garavito M, Dewitt DL (1996) Prostaglandin endoperoxide-H synthases-1 and -2. J Biol Chem 271(52):33157–33160
Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclooxygenase-2 gene. Biochem J 302(3):723–1127
Kujubu DA, Herschman HR (1992) Dexamethasone inhibits mitogen induction of the TS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 267(12):7991–7994
Herschman HR (1996) Prostaglandin synthase-2. Biochim Biophys Acta 1299(1):125–140
Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclooxygenase-2 gene. Biochem J 302(3):723–727
Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurones: regulation by synaptic activity and glucocorticoids. Neuron 11(4):371–386
Simmons DL, Xie W, Chipman JG, Evett GE (1991) Multiple cyclooxygenases: cloning of a mitogen-inducible form. In: Bailey JM (ed) Prostaglandins, leukotrienes, lipoxins and PAF. Plenum Press, New York, pp67–88
Walenga RW, Kester M, Coroneos E, Butcher S, Dwivedi R, Statt C (1996) Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro. Prostaglandins 52(5):341–359
Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94(6):2504–2510
Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL (1998) Subcellular localisation of prostaglandin endoperoxidase H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 273(16):9886–9893
Fitzpatrick FA, Soberman R (2001) Regulated formation of eicosanoids. J Clin Invest 107(11):1347–1351
Murakami M, Naraba H, Tanioka T, Semmyo N, Nkatari Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostalglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275(42):32783–32792
Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275(42):32775–32782
Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czemiak PM (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase-2. Nature 378(6555):406–409
Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK (1997) Multiple female reproductive failures in cyclooxygenase-2 deficient mice. Cell 91(2):197–208
Davis BJ, Lennard DE, Lee CA, Tiano HF, Morham SG, Wetsel WC, Langenbach R (1999) Anovulation in cyclooxygenase-2 deficient mice is restored by prostaglandin E2 and interleukin-1 beta. Endocrinology 140(6):2685–2695
Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA (1995) Prostaglandin synthase-2 gene disruption causes severe renal pathology in the mouse. Cell 83(3):473–482
Loftin CD, Trivedi DR, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM (2001) Failure of ductus arteriosus closure and remodelling in neonatal mice deficient in cyclooxygenase-1 and -2. Proc Natl Acad Sci USA 98(3):1059–1064
Rocca B, Spain LM, Pure E, langenbach R, Patrono C, Fitzgerald GA (1999) Distinct roles of prostaglandin H synthases-1 and -2 in T-cell development. J Clin Invest 103(10):1469–1477
Ohki S, Ogino N, Yamamoto S, Hayaishi O (1979) Prostaglandin hydrperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 254(3):829–836
Munroe DG, Wang EY, MacIntyre JP, Tam SS, Lee DH, Taylor GR, Zhou L, Plante RK, Kazami SM, Bauerle PA (1995) Novel intracellular signalling function of prostaglandin H synthase-1 in NF-kappa β activation. J Inflamm 45(4):260–268
Josephy PD, Eling TE, Mason RP (1983) Co-oxidation of benzidine by prostaglandin synthase and comparison with the action of horseradish peroxidase. J Biol Chem 258(9):5561–5569
Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90(6):455–460
Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000) Cyclooxygenase-2 is expressed in human pulmonary, colonic and mammary tumours. Cancer 89(12):2637–2645
Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632–635
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676–1681
Boland GP, Butt IP, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90:423–429
Kelly LM, Hill ADK, Kennedy S, Connolly EM, Ramanath R, Teh S, Dijkstra B, Purcell R, McDermott EW, O’Higgins N (2002) Lack of prognostic effect of COX-2 expression in primary breast cancer on short term follow-up. Eur J Surg Oncol 29:707–710
Singh Ranger G, Thomas V, Jewell A, Mokbel K (2004) Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 24(4):2349–2351
Kirkpatrick K, Ogunkolade W, Bustin S, Jenkins P, Ghilchik M, Mokbel K (2001) The mRNA expression of cyclooxygenase-2 and vascular endothelial growth factor in human breast cancer. Breast Cancer Res Treat 69(3):373
Watanabe O, Shimizu T, Imamura H, Kinoshita J, Utada Y, Okabe T, Kimura K, Hirano A, Yoshimatsu K, Aiba M, Ogawa K (2003) Expression of cyclooxygenase-2 in malignant and benign breast tumours. Anticancer Res 23(4):3215–3221
Yoshimura N, Sano H, Okamoto M, Akioka K, Ushogome H, Kadotani Y, Yoshimura R, Nobori S, Higuchi A, Ohmori Y, Nakamura K (2003) Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg Today 33:805–811
Zhao XQ, Pang D, Xue YW (2003) Expression of the cyclooxygenase-2 gene in human breast carcinoma. Zhongua Wai Ke Za Zhi 41(6):427–429
Guo GL, Yao ZX, Wu J (2003) The clinical significance of expression of cyclooxygenase-2 gene in breast cancer. Zhongua Yi Xue Za Zhi 83(19):1661–1664
Singh Ranger G, Kirkpatrick KL, Clark GM, Mokbel K (2003) Cyclooxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer. Curr Med Res Opin 19(2):131–134
Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclooxygenase-2 gene. Biochem J 302(3):723–727
Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takedo O, Takahashi E, Tanabe T (1994) Characterisation of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 221:889–897
Chen C-Y, Shyu A-B (1995) AU-rich elements; characterisation and importance in mRNA degradation. Trends Biochem Sci 20:465–470
Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T (1994) Induction of cyclooxygenase-2 by interleukin 1-alpha. Evidence for post-transcriptional regulation. J Biol Chem 269:11769–11775
Srivasta SK, Tetsuka T, Daphna-Iken D, Morrison AR (1994) IL 1 beta stabilises COX II mRNA in renal mesangial cells; role of 3′ untranslated region. Am J Physiol 36:F504–F508
Evett GE, Xie W, Chipman JG, Robertson DL, Simmons DL, Prostaglandin GH (1993) Synthase isoenyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens and oncogenes. Arch Biochem Biophys 306:169–177
Ristimaki A, Narko K, Hla T (1996) Downregulation of cytokine-induced cyclooxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 318(1):325–331
Sorlie T, Perou CM, Tibshirani R (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS USA 98:10869–10874
Brueggemeier RW, Richards JA, Petrel TA (2003) Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol 86:501–507
Read DL, Greene GL, Katzenellenbogen BS (1989) Regulation of estrogen receptor messenger ribonulcelic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. Mol Endocrinol 3(2):295–304
Katzenellenbogen BS, Norman MJ (1990) Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I serum, and estrogen. Endocrinology 126(2):891–898
Cho H, Aronica SM, Katzenellenbogen BS (1994) Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3′, 5′-Monophosphate, Estradiol, Insulin-like growth factor-I serum, and serum factors. Endocrinology 134(2):658–664
Vienonen A, Syvala H, Miettinen S, Tuohimaa P, Ylikomi T (2002) Expression of progesterone receptor isoforms A and B is differentially regulated by estrogen in different breast cancer cell lines. J Steroid Biochem Mol Biol 80:307–313
Salhab M, Singh Ranger G, Mokbel R, Jouhra F, Jiang WG, Mokbel K (2007) Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer (in press)
Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T, Wakabayashi K (2000) Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo [4,5,6] pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91(9):886–892
Howe LR, Crawford HC, Subbaramaiah K, Haassell JA, Dannenberg AJ, Brown AMC (2001) PEA-3 is upregulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem 276(23):20108–20115
Liu CH, Chang SH, narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21):18563–18569
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in APC delta 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87(5):803–809
Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman L (2003) Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 63:2347–2350
Tan KB, Yong WP, Putti TC (2004) Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 44(1):24–28
Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C (2005) COX-2 expression in DCIS: correlation with VEGF, HER2/neu, prognostic molecular markers and clinicopathological features. Histopathology 46:561–568
Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ (2001) Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8(2):97–114
Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ (1996) Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56(19):4424–4429
Sheng H, Williams CS, Shao J, Liang P, Dubois RN, Beauchamp RD (1998) Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of the mitogen-activated protein kinase pathway. J Biol Chem 273(34):22120–22127
Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R (1999) Regulation of the cyclooxygenase-2 pathway by the HER-2 receptor. Oncogene 18(2):305–314
Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ (1997) Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 57(14):2890–2895
Xie W, Herschmann HR (1995) v-src induces prostaglandin synthase-2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 270(46):27622–27628
Xie W, Herschmann HR (1996) Transcriptional regulation of prostaglandin synthase-2 gene expression by platelet derived growth factor and serum. J Biol Chem 271(49):31742–31748
Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ (1999) Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274(16):10911–10915
Nolan RD, Danilowicz RM, Eling TE (1988) Role of arachidonic acid metabolism in the mitogenic response of BALB/c 3T3 fibroblasts to epidermal growth factor. Mol Pharmacol 33(6):650–656
Goin M, Pignataro O, Jimenez de Asua L (1993) Early cell cycle diacyglycerol (DAG) content and protein kinase C (PKC) activity enhancement potentiates prostaglandin F2 alpha (PGF2 alpha) induced mitogenesis in Swiss 3T3 cells. FEBS Lett 316(1):68–72
Bandyopadhyay GK, Imagawa W, Wallace D, Nandi S (1987) Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor. J Biol Chem 262(6):2750–2756
Huang M, Sharma S, Mao JT, Dubinett SM (1996) Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein synthesis. J Immunol 157(12):5512–5520
Stolina M, Sharma S, Zhu L, Dubinett SM (2000) Lung cancer cyclooxygenase-2 dependent inhibition of dendritic cell maturation and function. Proc Am Assoc Cancer Res 41:619
Rolland PH, Martin PM, Jacquerier J, Roland AM, Toga M (1980) Prostaglandin production in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64(5):1061–1070
James VHT, Reed MJ (1980) Steroid hormones and human cancer. Prog Cancer Res Ther 14:471–487
Zhao Y, Agarwal VR, Mendelsohn CR, Simpson ER (1996) Oestrogen biosynthesis proximal to a breast tumour is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137(12):5739–5742
Zhao Y, Agarwal VR, Mendelsohn CR, Simpson ER (1997) Transcriptional regulation of CYP19 (aromatase) gene expression in adipose stromal cells in primary culture. J Steroid Biochem Mol Biol 61(3–6):203–210
Yamamoto K, Arakawa T, Veda N, Yamamoto S (1995) Transcriptional roles of nuclear factor-interleukin-6 in the tumour necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270(52):31315–31320
Prescott SM, Fitzpatrick FA (2000) Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470(2):M69–M78
Wiese FW, Thompson PA, Kadlubar FF (2001) Carcinogen substrate specificity of human cyclooxygenase-1 and cyclooxygenase-2. Carcinogenesis 22(1):5–10
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis-induced by colon cancer cells. Cell 93(5):705–716
Gately S (2001) The contributions of cyclooxygenase-2 to tumour angiogenesis. Cancer Metastasis Rev 19(1–2):19–27
Kirkpatrick K, Ogunkolade W, Bustin S, Jenkins P, Ghilchik M, Mokbel K (2001) The mRNA expression of cyclooxygenase-2 and vascualr endothelial growth factor in human breast cancer. Breast Cancer Res Treat 69(3):373
Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11):1589–1594
Marnett LJ (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52(20):5575–5589
Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T, Yoshimoto T (1999) Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett 460(1):145–148
Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, Jang Y, Cho SH, Kim HK (2000) Co-expression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 41(1):82–88
Iawata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y (1996) Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87(6):602–611
Friedman GD, Ury HK (1980) Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 65(4):723–733
Paganini-Hill A, Cho A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 299(6710):1247–1250
Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 83(5):355–358
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW (1993) Aspirin use and risk of fatal cancer. Cancer Res 53(6):1322–1327
Harris RE, Kasbari S, Farrar WB (1999) Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 6(1):71–73
Schreinmachers DM, Everson RB (1994) Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5(2):138–146
Sharpe CR, Collett JP, McNutt M, Belzille E, Bowin JF, Hanley JA (2000) Nested case-control study of the effects of nonsteroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83(1):112–120
Cotterchio M, Krieger N, Sloan M, Steinegart A (2001) Non-steroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10(11):1213–1217
Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a metaanalysis. Br J Cancer 84(9):1188–1192
Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294(1):47–55
Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G (2001) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119(Suppl 1):39S–63S
Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res 60(8):2101–2103
Suzui N, Sugie S, Rahman KM, Ohnishi M, Yoshimi N, Wakabayashi K, Mori H (1997) Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenyl-imidazole [4,5-b] pyridine-induced mammary carcinogenesis in rats. Jpn J Cancer Res 88(8):705–711
Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000) Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor in a rat mammary tumour model. Oncol Rep 7(6):1377–1381
Chow LW, Wong JL, Toi M (2003) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol 86(3–5):443–447
Parret ML, Harris RL, Joarder FS, Ross MS, Clausen KP, Robertson FM (1997) Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 10:503–508
Kirtikara K, Morham SG, Raghow R, Laulederkind SJF, Kanekura T, Goorha S, Ballou LR (1998) Compensatory prostaglandin E2 biosynthesis in cyclooxygenase-1 or cyclooxygenase-2 null cells. J Exp Med 187(4):517–523
Juni P, Rutjes AWS, Dieppe PA (2002) Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 324:1287–1288
Levesque LE, Brophy JM, Zhang B (2005) The risk of myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142(7):481–489
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Adenoma prevention with celecoxib (APC) study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071–1080
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh-Ranger, G., Salhab, M. & Mokbel, K. The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 109, 189–198 (2008). https://doi.org/10.1007/s10549-007-9641-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9641-5